Clinical Trial Detail

NCT ID NCT02427620
Title A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

mantle cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Vincristine

Filgrastim

Dexamethasone

Cytarabine + Methotrexate

Leucovorin

Age Groups: adult

No variant requirements are available.